Clinical Trials Directory

435 clinical trials found.
Hematologic Malignancies and Cellular Therapy

We are doing this study to find out if an experimental drug called mosunetuzumab (the study drug) is a safe and effective option for low burden follicular lymphoma. We want to know how well it works in comparison to rituximab, which is the standard drug used to treat people with this diagnosis.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital, Duke Raleigh Hospital
Cancer Immunotherapy

We are doing this study to find out if an experimental drug called STK-012 (the study drug) is a safe and effective treatment for different types of cancer.

Compensation: No
Oncology
Diabetes Mellitus

We are doing this study to help connect people with type 1 diabetes to research studies they may be eligible to join as participants.

Compensation: Yes
Ages: 16-50
Non-Oncology
Duke University Hospital, Other
Radiation Oncology

We are doing this study to find out if it is better to give patients with low-risk breast cancer regional radiation therapy as part of their standard treatment after surgery or if it is better to not give radiation. Regional radiotherapy is currently the standard treatment after surgery for low-risk breast cancer but we do not know if it is necessary in all cases.

Compensation: No
Ages: 35-110
Oncology
Duke University Hospital, Duke Raleigh Hospital, Other
Breast Cancer

We are doing this study to find out if radiation to the axillary (armpit) lymph nodes is equally effective and causes fewer side effects than surgical removal of the lymph nodes in patients with breast cancer.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital
Breast Cancer

We are doing this study to find out if avelumab is a safe and effective option for triple negative metastatic breast cancer when it is combined with different anti-cancer drugs.

Compensation: No
Ages: 18-89
Oncology
Duke University Hospital
Hematologic Malignancies and Cellular Therapy

We are doing this study to find out if an experimental drug called TL-895 (the study drug) is a safe and effective option for people with indolent systemic mastocytosis.

Compensation: No
Oncology